When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Evoke Pharma (EVOK) underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA’s recent update ...

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only ...

The definition of successful GPOEM varied across studies. The most common definitions were a one-point reduction in gastroparesis cardinal symptom index (GCSI), a one-point reduction in GCSI with a 25 ...

Do you feel dizzy after eating? The feeling of dizziness after eating meals is common and can happen to anyone. While this ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Sepiapterin (PTC-923 (CNSA-001)) is under development for the treatment of moderate to severe diabetic gastroparesis, tetrahydrobiopterin (BH4) deficiency resulting in hyperphenylalaninemia and ...

Q. If you watch television and see the drug commercials, diabetes is the happiest disease you could hope to have. The ads ...

Metoclopramide (4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide) is a substituted benzamide derivative (Figure 1) with a chemical structure similar to procainamide but without anti ...

GIMOTI nasal spray was approved by the FDA for the relief of symptoms of acute and recurrent diabetic gastroparesis in adults in June 2020. The new patents, U.S. 17/366,839 and U.S. 17/366,818 ...

One of the key challenges in treating gastroparesis is ensuring effective drug absorption, as delayed stomach emptying often compromises the efficacy of orally administered medications. GIMOTI ...